Business Wire

CGTN

Share
CGTN:Why Did Xi Jinping Make Fujian His First Stop After Five-year Plan Approval?

As China's latest medium and long-term economic and social development plan was just approved at the country's top legislature, President Xi Jinping has left Beijing for his first inspection trip to east China's Fujian Province after the Two Sessions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323006017/en/

Xi's visits to an ecological tea garden and the Wuyishan National Park during the inspection show the importance he attaches to green, ecological development, which was also stressed in China's road map for development for the next five years and beyond.

Wuyi Mountain and ecological protection

Standing in the suburbs of Wuyishan City, Mount Wuyi entered UNESCO's list of World Heritage Sites in 1999. It covers an area of over 630 square kilometers and numerous types of tea are produced there.

Visiting mountains is usually arranged in Xi's inspection tours as construction of ecological civilization has always been stressed by the president.

In April 2020, Xi's first stop was also to visit the mountains. He went directly to the Qinling Mountains during his inspection in northwest China's Shaanxi Province to learn about ecological protection, urging officials to be guardians of ecological environment.

In August 2019, he went to northwest China's Gansu Province and visited the Qilian Mountains, underlining ecological protection as a national strategy.

On Monday, during his visit to the Wuyishan National Park, he encountered a group of tourists. "You can enjoy the mountain scenery in Wuyishan and enjoy the seascape in Xiamen City," he told the group.

Xi also visited the park's intelligent management center, where all the weather monitoring and services for biological resources within the park are conducted.

During the just-concluded Two Sessions, he said top-level design and comprehensive measures are needed to protect the ecosystems in mountains, rivers, forests, farmlands, lakes, grasslands and deserts.

Tea industry and rural vitalization

"In the past, the tea industry was a pillar in your fight against poverty, and it should become a pillar industry of rural vitalization in the future," Xi said on Monday at the tea garden.

He called for efforts to better cultivate a vibrant tea industry that takes advantage of Mount Wuyi's long history of tea culture, suitable climate, rich tea resources and the support of science and technology.

Shaking off poverty is not the finish line but the starting line of a new life and new endeavor, Xi said in February after announcing that China has secured a "complete victory" in its fight against poverty, urging efforts to effectively integrate the consolidation of poverty alleviation achievements and rural vitalization.

China detailed plans to fully promote the strategy of rural vitalization in the Chinese leadership's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035.

Under this development blueprint, the country will push the development of industries with distinctive rural characteristics, cultivate new industries and modes of business, and encourage entrepreneurship and innovation in rural areas.

During his stop at the tea garden, Xi was pleased when hearing that the quality of tea was greatly improved through ecological planting in recent years, under the guidance of the team of technology commissioners.

Agricultural talents, also called "technological commissioners," was an idea introduced by Xi, the then governor to Fujian Province in a 2002 article, which called for bonding officials and farmers.

The president has stressed the role of science and technology in poverty alleviation and rural revitalization many times, calling for efforts to promote science and technological innovation in agriculture to support all-around rural revitalization.

During the inspection, Xi also visited a park dedicated to Zhu Xi, a renowned Chinese philosopher in the 12th century, in Nanping City on Monday afternoon, learning about local efforts to pass on traditional culture.

https://news.cgtn.com/news/2021-03-23/Xi-Jinping-makes-Fujian-his-first-stop-after-Five-Year-Plan-approval-YRH8REcXW8/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye